Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Michael

Showing results (111-120 of 216) with videos related to

Pageof 22
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|September 29, 2016
High clinical and morphologic response using <sup>90</sup>Y-DOTA-octreotate sequenced with <sup>177</sup>Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumoursGrace Kong, Jason Callahan, Michael S Hofman, et al.
Asia-Pacific Journal of Clinical Oncology|October 5, 2010
The Clinical Oncological Society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapyChristine Carrington, Leanne Stone, Bogda Koczwara, et al.
International Journal of Radiation Oncology, Biology, Physics|March 3, 2009
Local control and survival following concomitant chemoradiotherapy in inoperable stage I non-small-cell lung cancerMarie-Pierre Campeau, Alan Herschtal, Greg Wheeler, et al.
Cancer Chemotherapy and Pharmacology|July 6, 2004
A randomized cross-over trial to determine the effect of Cremophor EL on the pharmacodynamics and pharmacokinetics of carboplatin chemotherapySherene Loi, Danny Rischin, Michael Michael, et al.
Clinical Colorectal Cancer|September 2, 2006
Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicityPaul L Mitchell, David Goldstein, Michael Michael, et al.
Investigational New Drugs|January 24, 2004
A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancerMichael Jefford, Michael Michael, Mark A Rosenthal, et al.
The Medical Journal of Australia|November 18, 2008
Long-term survival following chemoradiation for inoperable non-small cell lung cancerNikki M Plumridge, Michael J Millward, Danny Rischin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2007
Tolerability of accelerated chest irradiation and impact on survival of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer: review of a single institution's experienceMichael Ng, Jennifer Chong, Alvin Milner, et al.
Cancer Chemotherapy and Pharmacology|September 5, 2018
Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centreMichael Moloney, David Faulkner, Emma Link, et al.
Journal of Medical Imaging and Radiation Oncology|August 26, 2021
The predictive value of PET/CT for distant recurrences in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapyJoseph C Kong, Jennifer Ryan, Timothy Akhurst, et al.
Pageof 22

Showing results (111-120 of 216) with videos related to

Sort By:
Pageof 22
European Journal of Nuclear Medicine and Molecular Imaging|September 29, 2016
High clinical and morphologic response using <sup>90</sup>Y-DOTA-octreotate sequenced with <sup>177</sup>Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumoursGrace Kong, Jason Callahan, Michael S Hofman, et al.
Asia-Pacific Journal of Clinical Oncology|October 5, 2010
The Clinical Oncological Society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapyChristine Carrington, Leanne Stone, Bogda Koczwara, et al.
International Journal of Radiation Oncology, Biology, Physics|March 3, 2009
Local control and survival following concomitant chemoradiotherapy in inoperable stage I non-small-cell lung cancerMarie-Pierre Campeau, Alan Herschtal, Greg Wheeler, et al.
Cancer Chemotherapy and Pharmacology|July 6, 2004
A randomized cross-over trial to determine the effect of Cremophor EL on the pharmacodynamics and pharmacokinetics of carboplatin chemotherapySherene Loi, Danny Rischin, Michael Michael, et al.
Clinical Colorectal Cancer|September 2, 2006
Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicityPaul L Mitchell, David Goldstein, Michael Michael, et al.
Investigational New Drugs|January 24, 2004
A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancerMichael Jefford, Michael Michael, Mark A Rosenthal, et al.
The Medical Journal of Australia|November 18, 2008
Long-term survival following chemoradiation for inoperable non-small cell lung cancerNikki M Plumridge, Michael J Millward, Danny Rischin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2007
Tolerability of accelerated chest irradiation and impact on survival of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer: review of a single institution's experienceMichael Ng, Jennifer Chong, Alvin Milner, et al.
Cancer Chemotherapy and Pharmacology|September 5, 2018
Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centreMichael Moloney, David Faulkner, Emma Link, et al.
Journal of Medical Imaging and Radiation Oncology|August 26, 2021
The predictive value of PET/CT for distant recurrences in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapyJoseph C Kong, Jennifer Ryan, Timothy Akhurst, et al.
Pageof 22